The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Revisiting phage therapy: new applications for old resources
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products
Datsenko, K. A., & Wanner, B. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120163297 · Cited by 14,782
Bacteriophage resistance mechanisms
Labrie, S. J., Samson, J. E., & Moineau, S. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2315 · Cited by 2,397
A new logic for DNA engineering using recombination in Escherichia coli
Zhang, Y., Buchholz, F., Muyrers, J. P. P., & Stewart, A. F. (1998) · Nature Genetics · doi:10.1038/2417 · Cited by 1,222
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Phage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Dispersing biofilms with engineered enzymatic bacteriophage
Lu, T. K., & Collins, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704624104 · Cited by 895
Bacteriophage Host Range and Bacterial Resistance
Hyman, P., & Abedon, S. T. (2010) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(10)70007-1 · Cited by 819
Bacteriophage Endolysins as Novel Antimicrobials
Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012) · Future Microbiology · doi:10.2217/fmb.12.97 · Cited by 785
Phage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy
Lu, T. K., & Collins, J. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800442106 · Cited by 529
Long-circulating bacteriophage as antibacterial agents.
Merril, C. R., Biswas, B., Carlton, R., Jensen, N. C., Creed, G. J., Zullo, S., & Adhya, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3188 · Cited by 512
Phage-Antibiotic Synergy (PAS): β-Lactam and Quinolone Antibiotics Stimulate Virulent Phage Growth
Comeau, A., Tétart, F., Trojet, S. N., Prère, M. F., & Krisch, H. M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000799 · Cited by 488
Wagner, E., Cotten, M., Foisner, R., & Birnstiel, M. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4255 · Cited by 484
Bacteriophage lysins as effective antibacterials
Fischetti, V. A. (2008) · Current Opinion in Microbiology · doi:10.1016/j.mib.2008.09.012 · Cited by 477
Phage Choice, Isolation, and Preparation for Phage Therapy
Gill, J., & Hyman, P. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725311 · Cited by 441
Bacteriophage lytic enzymes: novel anti-infectives
Fischetti, V. A. (2005) · Trends in Microbiology · doi:10.1016/j.tim.2005.08.007 · Cited by 400
Nelson, D. C., Schmelcher, M., Rodriguez-Rubio, L., Klumpp, J., Pritchard, D. G., Dong, S., & Donovan, D. M. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00007-4 · Cited by 372
Phage therapy: past history and future prospects.
Carlton, R. M. (1999) · PubMed · Cited by 342
Frequency of morphological phage descriptions in the year 2000
Ackermann, H.-W. (2001) · Archives of Virology · doi:10.1007/s007050170120 · Cited by 340
Bacteriophage Endolysins as a Novel Class of Antibacterial Agents
Borysowski, J., Weber-Dąbrowska, B., & Górski, A. (2006) · Experimental Biology and Medicine · doi:10.1177/153537020623100402 · Cited by 338
A Method for Generation Phage Cocktail with Great Therapeutic Potential
Gu, J., Liu, X., Li, Y., Han, W., Lei, L., Yang, Y., Zhao, H., Gao, Y., Song, J., Lu, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031698 · Cited by 268
Drulis-Kawa, Z., Majkowska-Skrobek, G., Maciejewska, B., Delattre, A.-S., & Lavigne, R. (2012) · Current Protein & Peptide Science · doi:10.2174/138920312804871193 · Cited by 261
Taking aim on bacterial pathogens: from phage therapy to enzybiotics
Hermoso, J. A., García, J. L., & García, P. (2007) · Current Opinion in Microbiology · doi:10.1016/j.mib.2007.08.002 · Cited by 251
Phage therapy gets revitalized
Reardon, S. (2014) · Nature · doi:10.1038/510015a · Cited by 241
Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro
Ryan, E. M., Alkawareek, M. Y., Donnelly, R. F., & Gilmore, B. F. (2012) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2012.00977.x · Cited by 240
Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K. J., & Fischetti, V. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01625-09 · Cited by 233
Toward rational control of Escherichia coli O157:H7 by a phage cocktail
Tanji, Y., Shimada, T., Yoichi, M., Miyanaga, K., Hori, K., & Unno, H. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-003-1438-9 · Cited by 226
BRED: A Simple and Powerful Tool for Constructing Mutant and Recombinant Bacteriophage Genomes
Marinelli, L. J., Piuri, M., Swigoňová, Z., Balachandran, A., Oldfield, L. M., van Kessel, J. C., & Hatfull, G. F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003957 · Cited by 226
Phage Therapy for Plant Disease Control
Balogh, B., Jones, J., Iriarte, F., & Momol, M. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725302 · Cited by 220
Phage Neutralization by Sera of Patients Receiving Phage Therapy
Łusiak-Szelachowska, M., Żaczek, M., Weber-Dąbrowska, B., Międzybrodzki, R., Kłak, M., Fortuna, W., Letkiewicz, S., Rogóż, P., Szufnarowski, K., Jończyk-Matysiak, E., et al. (2014) · Viral Immunology · doi:10.1089/vim.2013.0128 · Cited by 218
Westwater, C., Kasman, L. M., Schofield, D. A., Werner, P. A., Dolan, J. W., Schmidt, M. G., & Norris, J. S. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1301-1307.2003 · Cited by 214
Chan, B. K., & Abedon, S. T. (2012) · Advances in Applied Microbiology · doi:10.1016/b978-0-12-394805-2.00001-4 · Cited by 212
Escherichia coli K1's Capsule Is a Barrier to Bacteriophage T7
Scholl, D., Adhya, S., & Merril, C. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.8.4872-4874.2005 · Cited by 205
service, P. (2007) · Research in Microbiology · doi:10.1016/j.resmic.2007.07.005 · Cited by 201
Datta, S., Costantino, N., Zhou, X., & Court, D. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709089105 · Cited by 198
Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage
Hagens, S., Habel, A., von Ahsen, U., von Gabain, A., & Bläsi, U. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3817-3822.2004 · Cited by 187
CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages
Martel, B., & Moineau, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku628 · Cited by 178
Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system
Kiro, R., Shitrit, D., & Qimron, U. (2014) · RNA Biology · doi:10.4161/rna.27766 · Cited by 158
Goodridge, L. D. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725348 · Cited by 155
Clostridium difficile phages: still difficult?
Hargreaves, K. R., & Clokie, M. R. J. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00184 · Cited by 139
What is needed for phage therapy to become a reality in Western medicine?
Brüssow, H. (2012) · Virology · doi:10.1016/j.virol.2012.09.015 · Cited by 139
Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7
Yoichi, M., Abe, M., Miyanaga, K., Unno, H., & Tanji, Y. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.08.003 · Cited by 136
Phage Therapy: Concept to Cure
Keen, E. C. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00238 · Cited by 135
Kim, K.-P., Cha, J., Jang, E., Klumpp, J., Hagens, S., Hardt, W., Lee, K., & Loessner, M. J. (2008) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2008.00028.x · Cited by 128
What are the limitations on the wider therapeutic use of phage?
Henein, A. E. (2013) · Bacteriophage · doi:10.4161/bact.24872 · Cited by 110
Marinelli, L. J., Hatfull, G. F., & Piuri, M. (2012) · Bacteriophage · doi:10.4161/bact.18778 · Cited by 109
Örmälä, A.-M., & Jalasvuori, M. (2013) · Bacteriophage · doi:10.4161/bact.24219 · Cited by 103
Recombineering Using RecTE from Pseudomonas syringae
Swingle, B. M., Bao, Z., Markel, E. J., Chambers, A., & Cartinhour, S. W. (2010) · Applied and Environmental Microbiology · doi:10.1128/aem.00911-10 · Cited by 94
Bacteriophage recombineering in the lytic state using the lambda red recombinases
Fehér, T., Karcagi, I., Blattner, F. R., & Pósfai, G. (2011) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2011.00292.x · Cited by 68
The Crystal Structure of λ-Gam Protein Suggests a Model for RecBCD Inhibition
Court, R., Cook, N., Saikrishnan, K., & Wigley, D. B. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.037 · Cited by 67
Taking Bacteriophage Therapy Seriously: A Moral Argument
Verbeken, G., Huys, I., Pirnay, J., Jennes, S., Чанішвілі, Н., Scheres, J. M. J. C., Górski, A., Vos, D. D., & Ceulemans, C. (2014) · BioMed Research International · doi:10.1155/2014/621316 · Cited by 58
Staedel, C., Hua, Z., Broker, T. R., et al. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12377673 · Cited by 56
Bacteriophages use an expanded genetic code on evolutionary paths to higher fitness
Hammerling, M. J., Ellefson, J. W., Boutz, D. R., Marcotte, E. M., Ellington, A. D., & Barrick, J. E. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1450 · Cited by 45
Davis, G. D., & Kayser, K. J. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-232-8 · Cited by 10
Cited by
VirSorter: mining viral signal from microbial genomic data
Roux, S., Enault, F., Hurwitz, B. L., & Sullivan, M. B. (2015) · PeerJ · doi:10.7717/peerj.985 · Cited by 1,106
Biofilms in the Food Industry: Health Aspects and Control Methods
Galié, S., García-Gutiérrez, C., Miguélez, E. M., Villar, C. J., & Lombó, F. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00898 · Cited by 964
A century of the phage: past, present and future
Salmond, G. P. C., & Fineran, P. C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3564 · Cited by 823
Molecular and Evolutionary Determinants of Bacteriophage Host Range
de Jonge, P. A., Nobrega, F. L., Brouns, S. J. J., & Dutilh, B. E. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.08.006 · Cited by 475
Self-citationMultidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals
Ibrahim, S., Al-Saryi, N., Al-Kadmy, I. M. S., & Aziz, S. N. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06690-6 · Cited by 388
Metadata
- Authors
- Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J.
- Venue
- Trends in Microbiology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 23
- Issue
- 4
- Pages
- 185-191
- ISSN
- 0966-842X (ISSN-L)
- OpenAlex
- W2040375736
- Cited by
- 310
- References
- 54
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.